Cell Analysis Global Market - Forecast to 2027

Publishing Date : January, 2021
Report Code : HCBT0103
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

 

Cells constitute discrete units of biological function and serve as starting points in a myriad of studies to identify and map many of the basic biochemical and physical processes of life. Cell analysis is important to understand, predict, and ultimately analyze factors that underlie cell health, proliferation, function, and death by using various technologies such as PCR, Sequencing, Microfluidics, Spectrometry, Microscopes, High content analysis and others. All these technologies play a major role in gene, protein and RNA expression analysis of cells, having application in research, diagnosis and therapeutics development. Continuous advancements in technologies significantly revealed the heterogeneity, which will further enhance the cell analysis application.

The cell analysis global market is expected to reach $33,542.0 million by 2027 growing at a mid-single-digit CAGR from 2020 to 2027 due to rising incidence of infectious and non-infectious diseases and demand for early detection, diagnosis & treatment, increasing government and private funding, increasing advancements in cell imaging technologies to reduce the cost & time during the drug discovery process, growing focusing on personalized medicine, the introduction of advanced technologies in single-cell analysis and emerging Asia-Pacific market. However, stringent government regulations, lack of skilled personnel to use advanced cell analysis Instruments, and the high cost of some of the instruments are expected to hamper the market growth.

The market for cell analysis is segmented based on technique, product, application, end-user and geography. The cell analysis techniques global market is segmented into PCR, Sequencing, Microfluidics and Microarrays, Spectrometry, Microscopy, Cytometry, High Content Analysis, Electrophoresis and Others. Among the techniques, the PCR segment accounted for the largest revenue in 2020 and is expected to grow at a mid-single-digit CAGR from 2020 to 2027. Microfluidics and Microarrays segment is the fastest-growing segment at a high single-digit CAGR from 2020 to 2027.

The cell analysis products market is mainly segmented into consumables, instruments, software and services. Among these, consumables commanded the largest revenue in 2020 and is expected to grow at a mid-single-digit CAGR from 2020 to 2027. The consumables are further sub-segmented into reagents, assay kits, microplates, cell culture consumables and others. Among the consumables sub-segments, the Reagents held the largest share in 2020 and is expected to grow at a mid-single-digit CAGR from 2020 to 2027. Assay kits is the fastest-growing segment at a mid single-digit CAGR from 2020 to 2027. The software and services market is estimated to be $xx million in 2020 and is expected to grow at a mid single-digit CAGR from 2020 to 2027.

The instrument segment is further classified into cell counters, Cell microarray and microfluidics, liquid handling systems, cytometers, microfluidic devices, high content screening (HCS) systems microplate readers, PCR devices, sequencing instruments, spectrometers, microscopes and others. Among instruments, the PCR instruments commanded the largest share in 2020 and is expected to grow at a low single-digit CAGR from 2020 to 2027. This is attributed to extensive use of PCR (qPCR) use in diagnostics and also advancement in PCR systems, the launch of advanced PCR instruments, automated workflows, increasing approvals of PCR bases assays for medical diagnosis and other applications. Cell Microarrays and Microfluidics is the fastest-growing segment at a mid single-digit CAGR from 2020 to 2027 due to increasing advancements in microfluidic technologies mainly for single-cell analysis applications.

The application market is categorized by processes, by field, and by therapeutic area. In the process of application, the market is segmented into cellular processes, signal transduction pathways, circulating tumor cells, single-cell analysis, epigenetic target analysis, subpopulation characterization, and drug and candidate screening. Cellular process application accounted for the largest revenue in 2020 and is expected to grow at a mid single-digit CAGR from 2020 to 2027 due to increasing cell-based research activities and an increase in funding. The sSingle-cell analysis market is the fastest-growing segment at a high single-digit CAGR from 2020 to 2027 due to increasing advancement in single-cell technologies. By field of application, the market is further segmented into forensic, therapeutics, cell imaging, biomarker research, genomic analysis, stem cell analysis, and diagnostics. Diagnostics held the largest revenue in 2020 and is expected to grow at a mid single-digit CAGR from 2020 to 2027 due to the outbreak of various infectious diseases like influenza, Ebola, COVID-19 in recent years, adoption of early screening, companion diagnostic tests, prenatal screening of genetic diseases, and advancements in analytical tools, etc. Stem cell analysis is the fastest-growing segment at a mid single-digit CAGR from 2020 to 2027 due to increasing government support for stem cell-based research and also increasing approval of stem cell-based therapies. The cell imaging market is further segmented into live-cell imaging which commanded the revenue of $xx million in 2020 and is expected to grow at a mid single-digit CAGR from 2020 to 2027. By therapeutic area, the market is further segmented into cancer research, infectious disease, genetic testing, immunology, and others. The Infectious diseases accounted for the largest revenue in 2020 and is expected to grow at a low single-digit CAGR from 2020 to 2027 due to increasing incidence of infectious disease have raised the utilization of cell analytical technologies in research and as well as diagnosis. Cancer research is the fastest-growing segment at a mid single-digit CAGR from 2020 to 2027.

The end-users market is segmented into hospitals & diagnostic laboratories, academic and research institutes, contract research organizations (CROs), pharmaceuticals and biotechnology companies, cell banks, and others. Hospitals & Diagnostic laboratories generated the largest revenue in 2020 and is expected to grow at a mid single-digit CAGR from 2020 to 2027. Contract Research Organizations is the fastest-growing segment at a mid single-digit CAGR from 2020 to 2027.

By geography, the cell analysis global market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of APAC) and Rest of the world (Brazil, Rest of Latin America and the Middle East & Africa). North America accounted for the largest revenue in 2020 and is expected grow at a mid single-digit CAGR from 2020 to 2027 due to increasing R&D expenditure, increasing funding for - cell-based research, increasing application cell analysis in drug discovery & development, increasing demand for personalized medicine; early disease detection, diagnosis and treatment, increasing focus in developing single-cell analysis technologies for various application in therapeutics, diagnostics and disease research.

The Asia-Pacific is the fastest-growing region in the cell analysis global market at a mid single-digit CAGR from 2020 to 2027 which is attributed to the increased scope for research activities in academic & research institutes, increasing outsourcing, increased incidence of chronic diseases (cancer) and infectious disease, increasing awareness about early screening (cancer) and prenatal test and their adoption in clinical care, increasing government and private investment for - cell-based research and also for the development & expansion single-cell analysis technologies and increasing number startup companies engaged in the development innovative solutions. However, lack of technical expertise, high cost of instruments, lack of skilled labors, and large scale clinical data challenges are some of the restraints for the cell analysis market in the region.

The cell analysis global market is competitive and all the players in this market are involved in innovating new and advanced products to maintain their market shares. The key players in the cell analysis global market include Agilent Technologies, Inc. (U.S.), Becton Dickinson and Company (U.S.), Bio-Rad Laboratories (U.S.), Danaher Corporation (U.S.), Illumine Inc. (U.S.), Merck KGAA (Germany), Olympus Corporation (Japan), PerkinElmer, Inc. (U.S.), Promega Corporation (U.S.), Qiagen N.V. (Netherlands) and Thermo Fisher Scientific, Inc. (U.S.).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • U.S.
  • Rest of North America
  • Europe
  • Germany
  • Italy
  • France
  • Rest of Europe
  • Asia-Pacific 
  • Japan
  • China
  • India
  • Rest of APAC
  • Rest of the World (Row)
  • Brazil
  • Rest of LATAM
  •  The Middle East and Africa   
  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     SCOPE OF THE REPORT
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN & DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.5     PRIMARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     RISING INCIDENCE OF INFECTIOUS AND NON-INFECTIOUS DISEASES AND DEMAND FOR EARLY DETECTION, DIAGNOSIS & TREATMENT
        • 3.3.1.2     INCREASING GOVERNMENT AND PRIVATE FUNDING
        • 3.3.1.3     INCREASING ADVANCEMENTS IN CELL IMAGING TECHNOLOGIES REDUCE THE COST AND TIME CONSUMPTION FOR THE DRUG DISCOVERY PROCESS
        • 3.3.1.4     GROWING FOCUS ON PERSONALIZED MEDICINE
        • 3.3.1.5     INTRODUCTION OF ADVANCED TECHNOLOGIES IN SINGLE-CELL ANALYSIS
        • 3.3.1.6     EMERGING ASIA PACIFIC CELL ANALYSIS MARKET
      • 3.3.2     RESTRAINTS & THREATS
        • 3.3.2.1     LACK OF SKILLED PERSONNEL TO USE ADVANCED CELL ANALYSIS INSTRUMENTS
        • 3.3.2.2     EXPENSIVE CELL ANALYSIS INSTRUMENTS
        • 3.3.2.3     MAINTAINING CONSISTENCY, REPRODUCIBILITY OF ASSAYS AND LACK OF STANDARDIZATION
        • 3.3.2.4     STRINGENT REGULATORY FRAMEWORK LIMITS ADVANCEMENTS IN CELLULAR ANALYSIS MARKET
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     U.S.
      • 3.4.2     EUROPE
      • 3.4.3     CHINA
      • 3.4.4     INDIA
      • 3.4.5     JAPAN
    • 3.5     FUNDING SCENARIO
    • 3.6     CELL ANALYSIS – DEALS, ACQUISITIONS AND NEW PRODUCT LAUNCH
      • 3.6.1     NEW PRODUCT LAUNCH
    • 3.7     DEALS AND ACQUISITION
    • 3.8     TECHNOLOGICAL ADVANCEMENTS
      • 3.8.1     INTRODUCTION
      • 3.8.2     CRISPER LIVE CELL IMAGING
      • 3.8.3     SINGLE-CELL MULTI-OMICS
      • 3.8.4     RAMAN LIVE CELL IMAGING
      • 3.8.5     DROPLET-BASED MICROFLUIDICS IN SINGLE-CELL ANALYSIS
      • 3.8.6     INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY IN SINGLE-CELL ANALYSIS (ICP-MS)
      • 3.8.7     DEEP LEARNING AND AI IN MICROSCOPY
      • 3.8.8     INTELLIGENT IMAGE-ACTIVATED CELL SORTING OR AI-DRIVEN CELL ISOLATION TECHNOLOGY
      • 3.8.9     ADVANCED SPATIAL TECHNOLOGIES IN CELL ANALYSIS
      • 3.8.10     DIGITAL MICROFLUIDIC ISOLATION OF SINGLE-CELLS FOR -OMICS (DISCO)
    • 3.9     PORTER’S FIVE FORCE ANALYSIS
      • 3.9.1     THREAT OF NEW ENTRANTS
      • 3.9.2     THREAT OF SUBSTITUTES
      • 3.9.3     COMPETITIVE RIVALRY
      • 3.9.4     BARGAINING POWER OF SUPPLIERS
      • 3.9.5     BARGAINING POWER OF BUYERS
    • 3.10     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.10.1     CELL ANALYSIS GLOBAL MARKET SHARE ANALYSIS
      • 3.10.2     MARKET SHARE ANALYSIS BY SINGLE-CELL ANALYSIS MAJOR PLAYERS
  • 4     CELL ANALYSIS GLOBAL MARKET, BY TECHNIQUES
    • 4.1     INTRODUCTION
      • 4.1.1     PCR (POLYMERASE CHAIN REACTION)
      • 4.1.2     SEQUENCING
      • 4.1.3     MICROFLUIDICS AND MICROARRAYS
      • 4.1.4     SPECTROMETRY
      • 4.1.5     MICROSCOPY
      • 4.1.6     CYTOMETRY
      • 4.1.7     HIGH CONTENT SCREENING
      • 4.1.8     ELECTROPHORESIS
      • 4.1.9     OTHERS
  • 5     CELL ANALYSIS GLOBAL MARKET, BY PRODUCTS
    • 5.1     INTRODUCTION
    • 5.2     CONSUMABLES
      • 5.2.1     ASSAY KITS
      • 5.2.2     REAGENTS
      • 5.2.3     MICROPLATES
      • 5.2.4     CELL CULTURE CONSUMABLES
      • 5.2.5     OTHERS
    • 5.3     INSTRUMENTS
      • 5.3.1     CELL COUNTERS
      • 5.3.2     CELL MICROARRAYS AND MICROFLUIDICS
      • 5.3.3     LIQUID HANDLING SYSTEMS
      • 5.3.4     CYTOMETERS
      • 5.3.5     HIGH CONTENT SCREENING SYSTEMS
      • 5.3.6     MICROPLATE READERS
      • 5.3.7     PCR INSTRUMENTS
      • 5.3.8     SEQUENCING INSTRUMENTS
      • 5.3.9     SPECTROMETERS
      • 5.3.10     MICROSCOPES
      • 5.3.11     OTHER INSTRUMENTS
    • 5.4     SOFTWARE AND SERVICES
  • 6     CELL ANALYSIS GLOBAL MARKET, BY APPLICATION
    • 6.1     INTRODUCTION
    • 6.2     CELL ANALYSIS GLOBAL MARKET, BY PROCESS OF APPLICATION
      • 6.2.1     CELLULAR PROCESSES
      • 6.2.2     SIGNAL TRANSDUCTION PATHWAY
      • 6.2.3     CIRCULATING TUMOR CELLS
      • 6.2.4     SINGLE-CELL ANALYSIS
      • 6.2.5     EPIGENETIC TARGET ANALYSIS
      • 6.2.6     SUBPOPULATION CHARACTERIZATION
      • 6.2.7     DRUG AND CANDIDATE SCREENING
    • 6.3     CELL ANALYSIS GLOBAL MARKET, BY FIELD OF APPLICATION
      • 6.3.1     FORENSICS
      • 6.3.2     THERAPEUTICS
      • 6.3.3     GENOMIC ANALYSIS
      • 6.3.4     STEM CELL ANALYSIS
      • 6.3.5     BIOMARKER RESEARCH
      • 6.3.6     CELL IMAGING
        • 6.3.6.1     LIVE-CELL IMAGING
      • 6.3.7     DIAGNOSTICS
    • 6.4     CELL ANALYSIS GLOBAL MARKET, BY THERAPEUTIC AREA OF APPLICATIONS
      • 6.4.1     CANCER RESEARCH
      • 6.4.2     GENETIC TESTING
      • 6.4.3     INFECTIOUS DISEASES
      • 6.4.4     IMMUNOLOGY
      • 6.4.5     OTHERS
  • 7     CELL ANALYSIS GLOBAL MARKET, BY END-USERS
    • 7.1     INTRODUCTION
    • 7.2     HOSPITALS AND DIAGNOSTIC LABORATORIES
    • 7.3     ACADEMIC & RESEARCH LABORATORIES
    • 7.4     PHARMACEUTICALS AND BIOTECH COMPANIES
    • 7.5     CONTRACT RESEARCH ORGANISATIONS
    • 7.6     CELL BANKS
    • 7.7     OTHERS
  • 8     REGIONAL MARKET ANALYSIS
    • 8.1     INTRODUCTION
    • 8.2     NORTH AMERICA
      • 8.2.1     UNITED STATES OF AMERICA
      • 8.2.2     REST OF NORTH AMERICA
    • 8.3     EUROPE
      • 8.3.1     GERMANY
      • 8.3.2     FRANCE
      • 8.3.3     ITALY
      • 8.3.4     REST OF EUROPE
    • 8.4     ASIA PACIFIC
      • 8.4.1     JAPAN
      • 8.4.2     CHINA
      • 8.4.3     INDIA
      • 8.4.4     REST OF APAC
    • 8.5     REST OF THE WORLD
      • 8.5.1     BRAZIL
      • 8.5.2     REST OF LATIN AMERICA
      • 8.5.3     MIDDLE EAST AND AFRICA
  • 9     COMPETITIVE LANDSCAPE
    • 9.1     INTRODUCTION
    • 9.2     NEW PRODUCT LAUNCH
    • 9.3     APPROVAL
    • 9.4     AGREEMENTS, PARTNERSHIPS AND COLLABORATIONS
    • 9.5     ACQUISITIONS
    • 9.6     OTHERS
  • 10     MAJOR PLAYER PROFILES
    • 10.1     AGILENT TECHNOLOGIES, INC.
      • 10.1.1     OVERVIEW
      • 10.1.2     FINANCIALS
      • 10.1.3     PRODUCT PORTFOLIO
      • 10.1.4     KEY DEVELOPMENTS
      • 10.1.5     BUSINESS STRATEGY
      • 10.1.6     SWOT ANALYSIS
    • 10.2     BECTON DICKINSON AND COMPANY
      • 10.2.1     OVERVIEW
      • 10.2.2     FINANCIALS
      • 10.2.3     PRODUCT PORTFOLIO
      • 10.2.4     KEY DEVELOPMENTS
      • 10.2.5     BUSINESS STRATEGY
      • 10.2.6     SWOT ANALYSIS
    • 10.3     BIO-RAD LABORATORIES, INC
      • 10.3.1     OVERVIEW
      • 10.3.2     FINANCIALS
      • 10.3.3     PRODUCT PORTFOLIO
      • 10.3.4     KEY DEVELOPMENTS
      • 10.3.5     BUSINESS STRATEGY
      • 10.3.6     SWOT ANALYSIS
    • 10.4     DANAHER CORPORATION
      • 10.4.1     OVERVIEW
      • 10.4.2     FINANCIALS
      • 10.4.3     PRODUCT PORTFOLIO
      • 10.4.4     KEY DEVELOPMENTS
      • 10.4.5     BUSINESS STRATEGY.
      • 10.4.6     SWOT ANALYSIS
    • 10.5     ILLUMINA, INC.
      • 10.5.1     OVERVIEW
      • 10.5.2     FINANCIALS
      • 10.5.3     PRODUCT PORTFOLIO
      • 10.5.4     KEY DEVELOPMENTS
      • 10.5.5     BUSINESS STRATEGY
      • 10.5.6     SWOT ANALYSIS
    • 10.6     MERCK KGAA
      • 10.6.1     OVERVIEW
      • 10.6.2     FINANCIALS
      • 10.6.3     PRODUCT PORTFOLIO
      • 10.6.4     KEY DEVELOPMENTS
      • 10.6.5     BUSINESS STRATEGY
      • 10.6.6     SWOT ANALYSIS
    • 10.7     OLYMPUS CORPORATION
      • 10.7.1     OVERVIEW
      • 10.7.2     FINANCIALS
      • 10.7.3     PRODUCT PORTFOLIO
      • 10.7.4     KEY DEVELOPMENTS
      • 10.7.5     BUSINESS STRATEGY
      • 10.7.6     SWOT ANALYSIS
    • 10.8     PERKINELMER, INC.
      • 10.8.1     OVERVIEW
      • 10.8.2     FINANCIALS
      • 10.8.3     PRODUCT PORTFOLIO
      • 10.8.4     KEY DEVELOPMENTS
      • 10.8.5     BUSINESS STRATEGY
      • 10.8.6     SWOT ANALYSIS
    • 10.9     PROMEGA CORPORATION
      • 10.9.1     OVERVIEW
      • 10.9.2     FINANCIALS
      • 10.9.3     PRODUCT PORTFOLIO
      • 10.9.4     KEY DEVELOPMENTS
      • 10.9.5     BUSINESS STRATEGY
      • 10.9.6     SWOT ANALYSIS
    • 10.10     QIAGEN N.V
      • 10.10.1     OVERVIEW
      • 10.10.2     FINANCIALS
      • 10.10.3     PRODUCT PORTFOLIO
      • 10.10.4     KEY DEVELOPMENTS
      • 10.10.5     BUSINESS STRATEGY
      • 10.10.6     SWOT ANALYSIS
    • 10.11     THERMO FISHER SCIENTIFIC, INC.
      • 10.11.1     OVERVIEW
      • 10.11.2     FINANCIALS
      • 10.11.3     PRODUCT PORTFOLIO
      • 10.11.4     KEY DEVELOPMENTS
      • 10.11.5     BUSINESS STRATEGY
      • 10.11.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     CELL ANALYSIS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 2     CELL ANALYSIS GLOBAL MARKET REVENUE, BY TECHNIQUE, (2019-2027) ($MN)
      • TABLE 3     PCR IN CELL ANALYSIS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 4     SEQUENCING IN CELL ANALYSIS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 5     MICROFLUIDICS AND MICROARRAY IN CELL ANALYSIS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 6     SPECTROMETRY IN CELL ANALYSIS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 7     MICROSCOPY IN CELL ANALYSIS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 8     CYTOMETRY IN CELL ANALYSIS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 9     HIGH CONTENT SCREENING CELL ANALYSIS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 10     ELECTROPHORESIS CELL ANALYSIS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 11     OTHERS CELL ANALYSIS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 12     CELL ANALYSIS GLOBAL MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
      • TABLE 13     CELL ANALYSIS GLOBAL MARKET REVENUE, BY CONSUMABLES (2019-2027) ($MN)
      • TABLE 14     CELL ANALYSIS CONSUMABLES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 15     CELL ANALYSIS ASSAY KITS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 16     CELL ANALYSIS REAGENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 17     CELL ANALYSIS MICROPLATES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 18     CELL CULTURE CONSUMABLES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 19     OTHER CONSUMABLES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 20     CELL ANALYSIS GLOBAL MARKET REVENUE, BY INSTRUMENTS (2019-2027) ($MN)
      • TABLE 21     CELL ANALYSIS INSTRUMENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 22     CELL COUNTERS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 23     MICROARRAYS AND MICROFLUIDICS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 24     LIQUID HANDLING SYSTEMS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 25     CYTOMETERS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 26     HIGH CONTENT SCREENING GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 27     MICROPLATE READERS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 28     PCR INSTRUMENTS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 29     SEQUENCING INSTRUMENTS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 30     SPECTROMETERS INSTRUMENTS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 31     MICROSCOPY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 32     OTHER INSTRUMENTS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 33     SOFTWARE AND SERVICES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 34     CELL ANALYSIS GLOBAL MARKET REVENUE, BY PROCESS OF APPLICATION, (2019-2027) ($MN)
      • TABLE 35     CELLULAR PROCESSES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 36     SIGNAL TRANSDUCTION PATHWAY GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 37     CIRCULATING TUMOR CELLS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 38     SINGLE-CELL ANALYSIS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 39     EPIGENETIC TARGET ANALYSIS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 40     SUBPOPULATION CHARACTERIZATION GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 41     DRUG AND CANDIDATE SCREENING GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 42     CELL ANALYSIS GLOBAL MARKET REVENUE, BY FIELD OF APPLICATION, (2019-2027) ($MN)
      • TABLE 43     FORENSICS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 44     THERAPEUTICS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 45     GENOMIC ANALYSIS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 46     STEM CELL ANALYSIS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 47     BIOMARKER RESEARCH GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 48     CELL IMAGING GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 49     LIVE CELL IMAGING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 50     DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 51     CELL ANALYSIS GLOBAL MARKET REVENUE, BY THERAPEUTIC AREA OF APPLICATION, (2019-2027) ($MN)
      • TABLE 52     CANCER RESEARCH GLOBAL MARKET REVENUE BY REGION, (2019-2027) ($MN)
      • TABLE 53     GENETIC TESTING GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 54     INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 55     IMMUNOLOGY GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 56     OTHER THERAPEUTICS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • TABLE 57     CELL ANALYSIS GLOBAL MARKET REVENUE, BY END-USERS, (2019-2027) ($MN)
      • TABLE 58     HOSPITALS AND DIAGNOSTIC LABORATORIES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 59     ACADEMIC & RESEARCH LABORATORIES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 60     PHARMA & BIOTECH COMPANIES GLOBAL MARKET REVENUE BY REGION, (2019-2027) ($MN)
      • TABLE 61     CRO’S GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 62     CELL BANKS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 63     OTHER END-USERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 64     CELL ANALYSIS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 65     NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BY TECHNIQUE,(2019-2027) ($MN)
      • TABLE 66     NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BY PRODUCTS, (2019-2027) ($MN)
      • TABLE 67     NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BY CONSUMABLES, (2019-2027) ($MN)
      • TABLE 68     NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BY INSTRUMENTS, (2019-2027) ($MN)
      • TABLE 69     NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BY PROCESS OF APPLICATION, (2019-2027) ($MN)
      • TABLE 70     NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BY FIELD OF APPLICATION, (2019-2027) ($MN)
      • TABLE 71     NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BY THERAPEUTIC AREA OF APPLICATION, (2019-2027) ($MN)
      • TABLE 72     NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BY END-USER, (2019-2027) ($MN)
      • TABLE 73     NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 74     EUROPE CELL ANALYSIS MARKET REVENUE, BY TECHNIQUE,(2019-2027) ($MN)
      • TABLE 75     EUROPE CELL ANALYSIS MARKET REVENUE, BY PRODUCTS, (2019-2027) ($MN)
      • TABLE 76     EUROPE CELL ANALYSIS MARKET REVENUE, BY CONSUMABLES, (2019-2027) ($MN)
      • TABLE 77     EUROPE CELL ANALYSIS MARKET REVENUE, BY INSTRUMENTS, (2019-2027) ($MN)
      • TABLE 78     EUROPE CELL ANALYSIS MARKET REVENUE, BY PROCESS OF APPLICATION, (2019-2027) ($MN)
      • TABLE 79     EUROPE CELL ANALYSIS MARKET REVENUE, BY FIELD OF APPLICATION, (2019-2027) ($MN)
      • TABLE 80     EUROPE CELL ANALYSIS MARKET REVENUE, BY THERAPEUTIC AREA OF APPLICATION, (2019-2027) ($MN)
      • TABLE 81     EUROPE CELL ANALYSIS MARKET REVENUE, BY END-USER, (2019-2027) ($MN)
      • TABLE 82     EUROPE CELL ANALYSIS MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 83     APAC CELL ANALYSIS MARKET REVENUE, BY TECHNIQUE,(2019-2027) ($MN)
      • TABLE 84     APAC CELL ANALYSIS MARKET REVENUE, BY PRODUCTS, (2019-2027) ($MN)
      • TABLE 85     APAC CELL ANALYSIS MARKET REVENUE, BY CONSUMABLES, (2019-2027) ($MN)
      • TABLE 86     APAC CELL ANALYSIS MARKET REVENUE, BY INSTRUMENTS, (2019-2027) ($MN)
      • TABLE 87     APAC CELL ANALYSIS MARKET REVENUE, BY PROCESS OF APPLICATION, (2019-2027) ($MN)
      • TABLE 88     APAC CELL ANALYSIS MARKET REVENUE, BY FIELD OF APPLICATION, (2019-2027) ($MN)
      • TABLE 89     APAC CELL ANALYSIS MARKET REVENUE, BY THERAPEUTIC AREA OF APPLICATION, (2019-2027) ($MN)
      • TABLE 90     APAC CELL ANALYSIS MARKET REVENUE, BY END-USER, (2019-2027) ($MN)
      • TABLE 91     APAC CELL ANALYSIS MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 92     ROW CELL ANALYSIS MARKET REVENUE, BY TECHNIQUE, (2019-2027) ($MN)
      • TABLE 93     ROW CELL ANALYSIS MARKET REVENUE, BY PRODUCTS, (2019-2027) ($MN)
      • TABLE 94     ROW CELL ANALYSIS MARKET REVENUE, BY CONSUMABLES, (2019-2027) ($MN)
      • TABLE 95     ROW CELL ANALYSIS MARKET REVENUE, BY INSTRUMENTS, (2019-2027) ($MN)
      • TABLE 96     ROW CELL ANALYSIS MARKET REVENUE, BY PROCESS OF APPLICATION, (2019-2027) ($MN)
      • TABLE 97     ROW CELL ANALYSIS MARKET REVENUE, BY FIELD OF APPLICATION, (2019-2027)($MN)
      • TABLE 98     ROW CELL ANALYSIS MARKET REVENUE, BY THERAPEUTIC AREA OF APPLICATION, (2019-2027) ($MN)
      • TABLE 99     ROW CELL ANALYSIS MARKET REVENUE, BY END-USER, (2019-2027) ($MN)
      • TABLE 100     ROW CELL ANALYSIS MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 101     NEW PRODUCT LAUNCH (2019-2020)
      • TABLE 102     APPROVALS (2019-2020)
      • TABLE 103     AGREEMENTS, PARTNERSHIPS AND COLLABORATIONS (2019-2020)
      • TABLE 104     ACQUISITIONS (2019-2020)
      • TABLE 105     OTHERS (2019-2020)
      • TABLE 106     AGILENT TECHNOLOGIES, INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 107     AGILENT TECHNOLOGIES, INC.: TOTAL REVENUE BY SEGMENT, (2018-2020) ($MN)
      • TABLE 108     AGILENT TECHNOLOGIES, INC.: TOTAL REVENUE, BY REGION, (2018-2020) ($MN)
      • TABLE 109     BECTON DICKINSON AND COMPANY: TOTAL REVENUE AND R&D EXPENSES, (2018-2020)($MN)
      • TABLE 110     BECTON DICKINSON AND COMPANY: TOTAL REVENUE BY SEGMENT, (2018-2020) ($MN)
      • TABLE 111     BECTON DICKINSON AND COMPANY: LIFE SCIENCES REVENUE BY SUB - SEGMENT, (2018-2020) ($MN)
      • TABLE 112     BECTON DICKINSON AND COMPANY: TOTAL REVENUE, BY REGION, (2018-2020) ($MN)
      • TABLE 113     BIO-RAD LABORATORIES, INC: TOTAL REVENUE AND R&D EXPENSES, (2018-2020)(Q3) ($MN)
      • TABLE 114     BIO-RAD LABORATORIES: TOTAL REVENUE BY SEGMENT, (2018-2020) (Q3) ($MN)
      • TABLE 115     BIO-RAD LABORATORIES: TOTAL REVENUE, BY REGION, (2018-2020) (Q3) ($MN)
      • TABLE 116     DANAHER CORPORATION: TOTAL REVENUE AND R&D EXPENSES (2018-2020) (Q3) ($MN)
      • TABLE 117     DANAHER CORPORATION: TOTAL REVENUE, BY SEGMENT, (2018-2020)(Q3) ($MN)
      • TABLE 118     DANAHER CORPORATION: TOTAL REVENUE, BY REGION, (2018-2020) (Q3) ($MN)
      • TABLE 119     ILLUMINA, INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) (Q3) ($MN)
      • TABLE 120     ILLUMINA, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020)(Q3) ($MN)
      • TABLE 121     MERCK KGAA: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) (Q3) ($MN)
      • TABLE 122     MERCK KGAA: TOTAL REVENUE, BY SEGMENT, (2018-2020) (Q3) ($MN)
      • TABLE 123     MERCK KGAA COMPANY: TOTAL REVENUE, BY LIFE-SCIENCE SUB-SEGMENTS, (2018-2020) (Q3) ($MN)
      • TABLE 124     MERCK KGAA COMPANY: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) (Q3) ($MN)
      • TABLE 125     OLYMPUS CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2019 -2021) (Q2) ($MN)
      • TABLE 126     OLYMPUS CORPORATION: TOTAL REVENUE BY SEGMENT, (2019-2021) (Q2) ($MN)
      • TABLE 127     OLYMPUS CORPORATION: TOTAL REVENUE BY GEOGRAPHY, (2019-2021)(Q2) ($MN)
      • TABLE 128     PERKINELMER, INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) (Q3) ($MN)
      • TABLE 129     PERKINELMER, INC.: TOTAL REVENUE BY SEGMENT, (2018-2020) (Q3) ($MN)
      • TABLE 130     PERKINELMER, INC.: TOTAL REVENUE, BY REGION, (2018-2020) (Q3) ($MN)
      • TABLE 131     QIAGEN N.V.: TOTAL REVENUE AND R&D EXPENSES, (2018 -2020) (Q3) ($MN)
      • TABLE 132     QIAGEN N.V.: TOTAL REVENUE BY SEGMENT, (2018-2020)(Q3) ($MN)
      • TABLE 133     QIAGEN N.V.: TOTAL REVENUE, BY REGION, (2018-2020) (Q3)($MN)
      • TABLE 134     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) (Q3) ($MN)
      • TABLE 135     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY SEGMENT, (2018-2020) (Q3) ($MN)
      • TABLE 136     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020)(Q3) ($MN)

      LIST OF FIGURES

      • FIGURE 1     CELL ANALYSIS GLOBAL MARKET REVENUE, BY GEOGRAPHY (2019-2027)($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: CELL ANALYSIS GLOBAL MARKET
      • FIGURE 3     CELL ANALYSIS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     CELL ANALYSIS GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     CELL ANALYSIS GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
      • FIGURE 6     CELL ANALYSIS GLOBAL MARKET: MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     CELL ANALYSIS GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 9     CELL ANALYSIS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, (2020) (%)
      • FIGURE 10     SINGLE-CELL ANALYSIS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, (2020) (%)
      • FIGURE 11     CELL ANALYSIS GLOBAL MARKET SHARE, BY TECHNIQUES (2020) (%)
      • FIGURE 12     CELL ANALYSIS GLOBAL MARKET SHARE, BY PRODUCTS AND CONSUMABLES SUB-SEGMENT, (2020) ($MN)
      • FIGURE 13     CELL ANALYSIS GLOBAL MARKET REVENUE, BY INSTRUMENTS, (2020 VS 2027) ($MN)
      • FIGURE 14     CELL ANALYSIS GLOBAL MARKET SHARE, BY PROCESS OF APPLICATION (2020 V/S 2027) (%)
      • FIGURE 15     CELL ANALYSIS GLOBAL MARKET SHARE, BY FIELD OF APPLICATION (2020 V/S 2027) (%)
      • FIGURE 16     CELL ANALYSIS GLOBAL MARKET SHARE, BY THERAPEUTIC AREA OF APPLICATION (2020 V/S 2027) (%)
      • FIGURE 17     CELL ANALYSIS GLOBAL MARKET SHARE, BY END-USERS (2020 V/S 2027) (%)
      • FIGURE 18     CELL ANALYSIS MARKET GLOBAL REVENUE, BY REGION (2019-2027) ($MN)
      • FIGURE 19     CELL ANALYSIS GLOBAL MARKET REVENUE, BY GEOGRAPHY (2020) ($MN)
      • FIGURE 20     NORTH AMERICA CELL ANALYSIS MARKET SHARE, BY TECHNIQUE (2020) (%)
      • FIGURE 21     NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BY PRODUCT AND CONSUMABLES SUB - SEGMENT (2020) ($MN)
      • FIGURE 22     NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BY INSTRUMENTS (2020 VS 2027) ($MN)
      • FIGURE 23     NORTH AMERICA CELL ANALYSIS MARKET SHARE, BY PROCESS OF APPLICATION (2020 V/S 2027) (%)
      • FIGURE 24     NORTH AMERICA CELL ANALYSIS MARKET SHARE, BY FIELD OF APPLICATION (2020 V/S 2027) (%)
      • FIGURE 25     NORTH AMERICA CELL ANALYSIS MARKET SHARE, BY THERAPEUTIC AREA OF APPLICATION (2020 V/S 2027) (%)
      • FIGURE 26     NORTH AMERICA CELL ANALYSIS MARKET SHARE, BY END-USER (2020 V/S 2027) (%)
      • FIGURE 27     NORTH AMERICA CELL ANALYSIS MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
      • FIGURE 28     U.S CELL ANALYSIS MARKET REVENUE, BY PRODUCTS, PROCESS OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 29     U.S. CELL ANALYSIS MARKET REVENUE, BY FIELD OF APPLICATION, THERAPEUTIC AREA OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 30     U.S. CELL ANALYSIS APPLICATION MARKET REVENUE, BY END-USER (2020 V/S 2027) ($MN)
      • FIGURE 31     REST OF NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BY PRODUCTS, PROCESS OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 32     REST OF NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BY FIELD OF APPLICATION, THERAPEUTIC AREA OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 33     REST OF NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BY END-USER (2020 VS 2027) ($MN)
      • FIGURE 34     EUROPE CELL ANALYSIS MARKET SHARE, BY TECHNIQUE (2020) (%)
      • FIGURE 35     EUROPE CELL ANALYSIS MARKET REVENUE, BY PRODUCTS AND CONSUMABLES SUB-SEGMENT (2020) ($MN)
      • FIGURE 36     EUROPE CELL ANALYSIS MARKET REVENUE, BY INSTRUMENTS (2020 V/S 2027) ($MN)
      • FIGURE 37     EUROPE CELL ANALYSIS MARKET SHARE, BY PROCESS OF APPLICATION (2020 V/S 2027) (%)
      • FIGURE 38     EUROPE CELL ANALYSIS MARKET SHARE, BY FIELD OF APPLICATION (2020 V/S 2027) (%)
      • FIGURE 39     EUROPE CELL ANALYSIS MARKET SHARE, BY THERAPEUTIC AREA APPLICATION (2020 V/S 2027) (%)
      • FIGURE 40     EUROPE CELL ANALYSIS MARKET SHARE, BY END-USER (2020 V/S 2027) (%)
      • FIGURE 41     EUROPE CELL ANALYSIS MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
      • FIGURE 42     GERMANY CELL ANALYSIS MARKET REVENUE, BY PRODUCTS, PROCESS OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 43     GERMANY CELL ANALYSIS MARKET REVENUE, BY FIELD OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 44     GERMANY CELL ANALYSIS MARKET REVENUE, BY END-USER (2020 V/S 2027) ($MN)
      • FIGURE 45     FRANCE CELL ANALYSIS MARKET REVENUE, BY PRODUCTS, PROCESS OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 46     FRANCE CELL ANALYSIS MARKET REVENUE, BY FIELD OF APPLICATION, THERAPEUTIC AREA OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 47     FRANCE CELL ANALYSIS MARKET REVENUE, BY END-USER (2020 V/S 2027) ($MN)
      • FIGURE 48     ITALY CELL ANALYSIS MARKET REVENUE, BY PRODUCTS, PROCESS OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 49     ITALY CELL ANALYSIS MARKET REVENUE, BY FIELD OF APPLICATION, THERAPEUTIC AREA OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 50      ITALY CELL ANALYSIS MARKET REVENUE, BY END-USER (2020 V/S 2027) ($MN)
      • FIGURE 51     REST OF EUROPE CELL ANALYSIS MARKET REVENUE, BY PRODUCTS, PROCESS OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 52     REST OF EUROPE CELL ANALYSIS MARKET REVENUE, BY FIELD OF APPLICATION, THERAPEUTIC AREA OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 53     REST OF EUROPE CELL ANALYSIS MARKET REVENUE, BY END-USER (2020 V/S 2027) ($MN)
      • FIGURE 54     APAC CELL ANALYSIS MARKET SHARE, BY TECHNIQUE (2020) (%)
      • FIGURE 55     APAC CELL ANALYSIS MARKET REVENUE, BY PRODUCTS AND CONSUMABLES SUB-SEGMENT (2020) ($MN)
      • FIGURE 56     APAC CELL ANALYSIS MARKET REVENUE, BY INSTRUMENTS (2020 V/S 2027) ($MN)
      • FIGURE 57     APAC CELL ANALYSIS MARKET SHARE, BY PROCESS OF APPLICATION (2020 V/S 2027) (%)
      • FIGURE 58     APAC CELL ANALYSIS MARKET SHARE, BY FIELD OF APPLICATION (2020 V/S 2027) (%)
      • FIGURE 59     APAC CELL ANALYSIS MARKET SHARE, BY THERAPEUTIC AREA OF APPLICATION (2020 V/S 2027) (%)
      • FIGURE 60     APAC CELL ANALYSIS MARKET SHARE, BY END-USER (2020 V/S 2027) (%)
      • FIGURE 61     APAC CELL ANALYSIS MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
      • FIGURE 62     JAPAN CELL ANALYSIS MARKET REVENUE, BY PRODUCTS, PROCESS OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 63     JAPAN CELL ANALYSIS MARKET REVENUE, BY FIELD OF APPLICATION, THERAPEUTIC AREA OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 64     JAPAN CELL ANALYSIS MARKET REVENUE, BY END-USER (2020 VS 2027) ($MN)
      • FIGURE 65     CHINA CELL ANALYSIS MARKET REVENUE, BY PRODUCTS, PROCESS OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 66      CHINA CELL ANALYSIS MARKET REVENUE, BY FIELD OF APPLICATION, THERAPEUTIC AREA OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 67     CHINA CELL ANALYSIS MARKET REVENUE, BY END-USER (2020 V/S 2027) ($MN)
      • FIGURE 68     INDIA CELL ANALYSIS MARKET REVENUE, BY PRODUCTS, PROCESS OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 69     INDIA CELL ANALYSIS MARKET REVENUE, BY FIELD OF APPLICATION, THERAPEUTIC AREA OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 70     INDIA CELL ANALYSIS MARKET REVENUE, BY END-USER (2020 VS 2027) ($MN)
      • FIGURE 71     REST OF APAC CELL ANALYSIS MARKET REVENUE, BY PRODUCTS, PROCESS OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 72     REST OF APAC CELL ANALYSIS MARKET REVENUE, BY FIELD OF APPLICATION, THERAPEUTIC AREA OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 73     REST OF APAC CELL ANALYSIS MARKET REVENUE, BY END-USER (2020 V/S 2027) ($MN)
      • FIGURE 74     REST OF THE WORLD CELL ANALYSIS MARKET SHARE, BY TECHNIQUE (2020) (%)
      • FIGURE 75     REST OF THE WORLD CELL ANALYSIS MARKET SHARE, BY PRODUCTS AND CONSUMABLES SUB-SEGMENT (2020) ($MN)
      • FIGURE 76     REST OF THE WORLD CELL ANALYSIS MARKET REVENUE, BY INSTRUMENTS (2020 V/S 2027) ($MN)
      • FIGURE 77     REST OF THE WORLD CELL ANALYSIS MARKET SHARE, BY PROCESS OF APPLICATION (2020 V/S 2027) (%)
      • FIGURE 78     REST OF THE WORLD CELL ANALYSIS MARKET SHARE, BY FIELD OF APPLICATION (2020 V/S 2027) (%)
      • FIGURE 79     REST OF THE WORLD CELL ANALYSIS MARKET SHARE, BY THERAPEUTIC AREA APPLICATION (2020 V/S 2027) (%)
      • FIGURE 80     REST OF THE WORLD CELL ANALYSIS MARKET SHARE, BY END-USER (2020 V/S 2027) (%)
      • FIGURE 81     REST OF THE WORLD CELL ANALYSIS MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
      • FIGURE 82     BRAZIL CELL ANALYSIS MARKET REVENUE, BY PRODUCTS, PROCESS OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 83     BRAZIL CELL ANALYSIS MARKET REVENUE, BY FIELD OF APPLICATION, THERAPEUTIC AREA OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 84     BRAZIL CELL ANALYSIS MARKET REVENUE, BY END-USER (2020 V/S 2027) ($MN)
      • FIGURE 85     REST OF LATAM CELL ANALYSIS MARKET REVENUE, BY PRODUCTS, PROCESS OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 86     REST OF LATAM CELL ANALYSIS MARKET REVENUE, BY FIELD OF APPLICATION, THERAPEUTIC AREA OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 87     REST OF LATAM CELL ANALYSIS MARKET REVENUE, BY END-USER (2020 V/S 2027) ($MN)
      • FIGURE 88     MIDDLE EAST AND AFRICA CELL ANALYSIS MARKET REVENUE, BY PRODUCTS, PROCESS OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 89     MIDDLE EAST AND AFRICA CELL ANALYSIS MARKET REVENUE, BY FIELD OF APPLICATION, THERAPEUTIC AREA OF APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 90     MIDDLE EAST AND AFRICA CELL ANALYSIS MARKET REVENUE, BY END-USER (2020 V/S 2027) ($MN)
      • FIGURE 91     KEY GROWTH STRATEGIES (2019-2020)
      • FIGURE 92     SWOT: AGILENT TECHNOLOGIES
      • FIGURE 93     SWOT: BECTON DICKINSON AND COMPANY
      • FIGURE 94     SWOT: BIO-RAD LABORATORIES INC.
      • FIGURE 95     SWOT: DANAHER CORPORATION
      • FIGURE 96     SWOT: ILLUMINA INC.
      • FIGURE 97     SWOT: MERCK KGAA
      • FIGURE 98     SWOT: OLYMPUS CORPORATION
      • FIGURE 99     SWOT: PERKINELMER, INC
      • FIGURE 100     SWOT: PROMEGA CORPORATION
      • FIGURE 101     SWOT: QIAGEN N V
      • FIGURE 102     SWOT: THERMO FISHER SCIENTIFIC

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     1CELLBIO
      • 2     10X GENOMICS
      • 3     23ANDME
      • 4     ANDREAS HETTICH GMBH & CO. KG
      • 5     ABBEXA LTD
      • 6     ABCAM PLC.
      • 7     ABDOS LABTECH PVT, LTD.
      • 8     ABNOVA CORPORATION
      • 9     ABP BIOSCIENCES LLC
      • 10     AGILENT TECHNOLOGIES INC.
      • 11     AKADEUM LIFE SCIENCES
      • 12     ALIT LIFESCIENCES CO., LTD
      • 13     ALTONA DIAGNOSTICS GMBH
      • 14     ANALYTIK JENA AG
      • 15     ART ROBBINS INSTRUMENTS LLC
      • 16     AELIAN BIOTECHNOLOGY
      • 17     ABBOTT LABORATORIES, INC.
      • 18     AVIVA BIOSCIENCE
      • 19     ARRAYGEN TECHNOLOGIES PVT LTD
      • 20     ANCESTRY HEALTH
      • 21     BECTON DICKINSON AND COMPANY
      • 22     BIO VIEW LTD.
      • 23     BIO X CELL
      • 24     BIOCHROM LTD.
      • 25     BGI GROUP
      • 26     BIOFLUIDICA
      • 27     BITBIOME, INC.
      • 28     BIO-RAD LABORATORIES INC.
      • 29     BIOINGENTECH
      • 30     BIONEER CORPORATION
      • 31     BIORON GMBH
      • 32     BIO-TECHNE CORPORATION
      • 33     BLUE-RAY BIOTECH
      • 34     BRAND GMBH
      • 35     BROOKS LIFE SCIENCES
      • 36     BRUKER CORPORATION
      • 37     BENNUBIO INC.
      • 38     BIOSKRYB, INC.
      • 39     BIOAGILYTIX LABS, LLC
      • 40     BERRY GENOMICS CO., LTD
      • 41     CLEAVER SCIENTIFIC
      • 42     CAPP APS
      • 43     CEGAT GMBH
      • 44     CARL ZEISS AG
      • 45     CELL SIGNALING TECHNOLOGY, INC.
      • 46     CELLTOOL
      • 47     CHERRY BIOTECH
      • 48     CELSIUS THERAPEUTICS
      • 49     CYTOSMART TECHNOLOGIES B.V.
      • 50     CYTEK BIOSCIENCES
      • 51     CELL MICROSYSTEMS
      • 52     CELLINK
      • 53     CELTIC MOLECULAR DIAGNOSTICS
      • 54     CAPITALBIO CORPORATION
      • 55     CELL BIOLABS, INC.
      • 56     CORNING INC.
      • 57     DA AN GENE CO., LTD.,
      • 58     DANAHER CORPORATION
      • 59     DENOVIX INC.
      • 60     DIAGENODE SA
      • 61     DEEPCELL
      • 62     DLAB SCIENTIFIC CO., LTD.,
      • 63     DOLOMITE BIO
      • 64     EMEDGENE TECHNOLOGIES LTD
      • 65     ENZO LIFE SCIENCES INC.
      • 66     EPIGENOMICS AG
      • 67     EPPENDORF
      • 68     ETALUMA INC.
      • 69     EUROFINS SCIENTIFIC
      • 70     FLUIDIGM CORPORATION
      • 71     FLUXION BIOSCIENCES
      • 72     GENOMATIX AG
      • 73     GENXPRO GMBH (GERMANY
      • 74     HAMILTON COMPANY
      • 75     HAUSSER SCIENTIFIC
      • 76     HEROLAB GMBH
      • 77     HETTICH LAB TECHNOLOGY
      • 78     HORIBA, LTD
      • 79     HIGHQU GMBH
      • 80     INCELLDX
      • 81     INSCOPIX
      • 82     ILLUMINA INC.
      • 83     ISOPLEXIS
      • 84     JASCO ANALYTICAL INSTRUMENTS
      • 85     JEOL LTD
      • 86     KROMATID
      • 87     KEYENCE CORPORATION
      • 88     KYRATEC
      • 89     HELENA LABORATORIES CORPORATION
      • 90     LABGENE SCIENTIFIC SA
      • 91     LGC LTD (BIOSEARCH TECHNOLOGIES)
      • 92     LUCIGEN CORPORATION
      • 93     LUMINEX CORPORATION
      • 94     LUNGLIFE AI, INC
      • 95     LONZA GROUP
      • 96     LW SCIENTIFIC
      • 97     MEIJI TECHNO CO., LTD
      • 98     MERCK KGAA
      • 99     MICRO-SHOT TECHNOLOGY LTD.
      • 100     MILTENYIL BIOTEC GMBH
      • 101     MISSION BIO, INC.
      • 102     MENARINI SILICON BIOSYSTEMS
      • 103     MACROGEN INC
      • 104     NANOLIVE SA
      • 105     NOVOGENE CO. LTD
      • 106     NANOSTRING TECHNOLOGIES
      • 107     NAMOCELL INC.
      • 108     NIKON CORPORATION
      • 109     NEXCELOM BIOSCIENCE
      • 110     NEBULA GENOMICS
      • 111     OPTIKA SRL
      • 112     OLYMPUS CORPORATION
      • 113     OXFORD NANOPORE TECHNOLOGIES, LTD.
      • 114     PARADIGM4
      • 115     PERKINELMER
      • 116     PICOQUANT GMBH
      • 117     PROMEGA CORPORATION
      • 118     PROMOCELL
      • 119     PACIFIC BIOSCIENCES
      • 120     PROTEONA PTE. LTD.
      • 121     QIAGEN N.V
      • 122     QUEST DIAGNOSTICS
      • 123     RENISHAW PLC
      • 124     ROCHE DIAGNOSTICS
      • 125     RARECYTE, INC
      • 126     SINGLERON BIOTECHNOLOGIES. INC
      • 127     SARTORIUS AG
      • 128     SHIMADZU CORPORATION
      • 129     SINACLON
      • 130     SINGLE-CELL DISCOVERIES
      • 131     SONY BIOTECHNOLOGY
      • 132     SPHERE FLUIDICS
      • 133     SCAILYTE AG
      • 134     STEMCELL TECHNOLOGIES
      • 135     SYSMEX COPERATION
      • 136     SCIPIO BIOSCIENCE S.A.S
      • 137     S2 GENOMICS, INC.
      • 138     THERMO FISHER SCIENTIFIC
      • 139     THINKCYTE
      • 140     TECAN GROUP LTD.
      • 141     TOMOCUBE INC.
      • 142     TAKARA BIO
      • 143     VISITRON SYSTEMS GMBH
      • 144     VIZGEN, INC.
      • 145     YOKOGAWA ELECTRIC CORPORATION
      • 146     ZYMO RESEARCH